Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)
Condition: Chronic Sinusitis; Nasal Polyposis
MeSH terms: Sinusitis; Nasal Polyps; Chronic Disease
Intervention: S8 Sinus Implant
Intervention description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 50.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: corticosteroid; implant

Summary:

      The ENCORE Study is designed to evaluate the repeat administration of the S8 Sinus Implant in
      chronic sinusitis (CS) patients with recurrent nasal polyps.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Patient has provided written informed consent using a form approved by the reviewing
             institutional review board (IRB) and sponsor.

          2. Patient is ≥ 18 years of age.

          3. Patient is willing and able to comply with protocol requirements.

          4. Patient has a confirmed diagnosis of CS with nasal polyps, as defined in the 2016
             "International Consensus Statement on Allergy and Rhinology".

          5. Patient has undergone prior ESS including bilateral total ethmoidectomy at least 90
             days prior to screening.

          6. Patient has evidence of bilateral ethmoid sinus obstruction due to polyposis
             warranting intervention (polyp grade ≥ 2 on each side).

          7. Patient is able to tolerate daily use of Mometasone Furoate Nasal Spray (MFNS).

          8. Patient is able to tolerate topical/local anesthesia.

          9. In the opinion of the investigator, patient's ethmoid sinus anatomy is amenable to
             in-office bilateral placement of the S8 Sinus Implant (i.e., able to pass into the
             middle meatus on both sides the S8 Sinus Implant with 20 mm in nominal length and 7 mm
             in compressed diameter).

         10. Female patients of reproductive potential must not be pregnant or nursing and must
             agree to not become pregnant during their participation in the study.

         11. Female patients of childbearing potential must agree to use consistent and acceptable
             method(s) of birth control during their participation in the study.

        Exclusion Criteria:

          1. Patient has extensive ethmoid sinus polyp grade (grade 4 on at least one side).

          2. Patient has extensive adhesions/synechiae (grade 3 or 4).

          3. Patient has used parenteral and injected steroids (e.g., Kenalog injection) during 30
             days prior to the baseline procedure.

          4. Patient has used oral steroids, budesonide or other sinus steroid irrigations/rinses,
             nebulized steroids administered nasally or budesonide drops during 14 days prior to
             the baseline procedure.

          5. Patient has oral-steroid dependent condition such as chronic obstructive pulmonary
             disease (COPD) or asthma.

          6. Patient has known history of allergy or intolerance to corticosteroids or mometasone
             furoate.

          7. Patient has used monoclonal antibodies for asthma, allergies or nasal polyps (e.g.,
             Dupixent, Nucala, Xolair) during 30 days prior to the baseline procedure.

          8. Patient requires monoclonal antibodies for asthma, allergies or nasal polyps during
             the duration of the study.

          9. Patient has presence of physical obstruction that would preclude access and placement
             of the S8 Sinus Implant in the middle meatus (e.g., severe septal deviation, septal
             spur, very small middle meatus, total obstruction of the sinonasal passage with severe
             adhesion, scarring, polypoid edema or polyps).

         10. Patient has known history of human immunodeficiency virus (HIV) or immunoglobulin G or
             A subclass deficiency.

         11. Patient has clinical evidence of acute sinusitis (AS), as defined in the 2016
             "International Consensus Statement on Allergy and Rhinology".

         12. Patient has clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone
             erosion on prior computed tomography (CT) scan, necrotic sinus tissue).

         13. Patient has evidence of severe concomitant disease or condition expected to compromise
             survival or ability to complete assessments during the 365-day study follow-up period
             (e.g., cancer).

         14. Patient is currently participating in another clinical study.

         15. Patient has previously undergone ESS and experienced a cerebrospinal fluid (CSF) leak
             or has residual compromised vision as a result of a complication in a prior ESS
             procedure.

         16. Patient has known dehiscence of the lamina papyracea.

         17. Patient has evidence of active tuberculosis or active viral illness (e.g., ocular
             herpes simplex, chickenpox, measles).

         18. Patient has known history or diagnosis of glaucoma or ocular hypertension (prior
             ocular exam with intraocular pressure of >21 mmHg and pressure lowering medication
             given) or posterior subcapsular cataract.